این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
صفحه اصلی
درباره پایگاه
فهرست سامانه ها
الزامات سامانه ها
فهرست سازمانی
تماس با ما
JCR 2016
جستجوی مقالات
چهارشنبه 19 آذر 1404
Medical Laboratory Journal
، جلد ۱۶، شماره ۶، صفحات ۰-۰
عنوان فارسی
چکیده فارسی مقاله
کلیدواژههای فارسی مقاله
عنوان انگلیسی
Anti-SARS-CoV-2 IgG Response after First and Second Dose of COVID-19 Vaccine
چکیده انگلیسی مقاله
Background and objectives: Pandemics have serious adverse impacts on public health, economy, social structure, and overall growth and development of a nation. Such impacts can be mitigated by timely introduction of effective vaccination programs. This was successfully achieved in India. This study was performed to compare the anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) responses after first and second dose of coronavirus disease 2019 (COVID-19) vaccination. Methods: This cross-sectional study included 60 people who were vaccinated with the AstraZeneca vaccine at Karnataka Institute of Medical Sciences, Hubballi, India. The subjects were divided into two groups. Group I included 30 people who had received a single dose of the vaccine, and group II included 30 people who had received two doses of the vaccine. Exclusion criteria included having a history of influenza like illness/severe acute respiratory infection/proven COVID-19 infection in past 6 months. The antibody response was measured by the Anti-SARS-CoV-2 IgG test using the VITROS Anti-SARS-CoV-2 IgG Reagent Pack. Results: We observed that 97% of the subjects had reactive IgG antibodies after receiving two doses of the vaccine, whereas only 83% of the subjects developed antibodies after a single dose of the vaccine. A positive correlation was observed between the development of reactive antibodies and the duration between the first dose and the second dose (r=0.24). Conclusion: Based on the results, the two-dose vaccination with the AstraZeneca vaccine is beneficial over the single-dose vaccination for protection against COVID-19. Moreover, increasing the duration between doses might improve the antibody response.
کلیدواژههای انگلیسی مقاله
COVID-19,COVID-19 Vaccines,Pandemics
نویسندگان مقاله
| Muragendraswami Astagimath
Department of Biochemistry, Karnataka Institute of Medical Sciences, Hubballi, Karnataka, India
| Suman Doddamani
Department of Biochemistry, Karnataka Institute of Medical Sciences, Hubballi Karnataka, India
| Vishwanath Patil
Assistant Professor,Department of General Medicine, Karnataka Institute of medical sciences, Hubballi, Karnataka, India.
| Raviraja Aryapu
Department of General Medicine, Karnataka Institute of medical sciences, Hubballi, Karnataka, India
نشانی اینترنتی
http://mlj.goums.ac.ir/browse.php?a_code=A-10-1237-1&slc_lang=en&sid=1
فایل مقاله
فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
en
موضوعات مقاله منتشر شده
ایمنی شناسی
نوع مقاله منتشر شده
تحقیقی
برگشت به:
صفحه اول پایگاه
|
نسخه مرتبط
|
نشریه مرتبط
|
فهرست نشریات